Robert J Young

List of Publications by Year in Descending Order

57 papers	2,123 citations	21 h-index	45 g-index
62 ext. papers	2,471 ext. citations	5.5 avg, IF	5.23 L-index

#	Paper	IF	Citations
57	Method Development and Application of an Accelerated Solution Stability Screen for Drug Discovery. *SLAS Discovery*, **2020**, 25, 1191-1196	3.4	0
56	Targeting the Regulatory Site of ER Aminopeptidase 1 Leads to the Discovery of a Natural Product Modulator of Antigen Presentation. *Journal of Medicinal Chemistry*, **2020**, 63, 3348-3358	8.3	12
55	Facts, Patterns, and Principles in Drug Discovery: Appraising the Rule of 5 with Measured Physicochemical Data. *Journal of Medicinal Chemistry*, **2020**, 63, 10091-10108	8.3	26
54	Decaprenylphosphoryl-□d-ribose Oxidase Inhibitors: Expeditious Reconstruction of Suboptimal Hits into a Series with Potent in Vivo Activity. *Journal of Medicinal Chemistry*, **2020**, 63, 2557-2576	8.3	8
53	Revisiting the Language of Glycoscience: Readers, Writers and Erasers in Carbohydrate Biochemistry. *ChemBioChem*, **2020**, 21, 423-427	3.8	12
52	Identification of 2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-N-phenylpropanamides as a novel class of potent DprE1 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2020**, 30, 127192	2.9	3
51	Physicochemical properties and transporters: keys to efficacious antitubercular drugs?. *RSC Medicinal Chemistry*, **2020**, 12, 43-56	3.5	8
50	Identification and Optimization of Novel Small c-Abl Kinase Activators Using Fragment and HTS Methodologies. *Journal of Medicinal Chemistry*, **2019**, 62, 2154-2171	8.3	10
49	Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 821-825	2.9	7
48	Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 1454-1458	2.9	4
47	Identification via a Parallel Hit Progression Strategy of Improved Small Molecule Inhibitors of the Malaria Purine Uptake Transporter that Inhibit Parasite Proliferation. *ACS Infectious Diseases*, **2019**, 5, 1738-1753	5.5	4
46	Using Physicochemical Measurements to Influence Better Compound Design. *SLAS Discovery*, **2019**, 24, 791-801	3.4	11
45	The Mechanism of Acetyl Transfer Catalyzed by Mycobacterium tuberculosis GlmU. *Biochemistry*, **2018**, 57, 3387-3401	3.2	6
44	Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. *Journal of Medicinal Chemistry*, **2018**, 61, 6421-6467	8.3	48
43	Expanding the medicinal chemistry synthetic toolbox. *Nature Reviews Drug Discovery*, **2018**, 17, 709-727	64.1	223
42	The role and impact of high throughput biomimetic measurements in drug discovery. *ADMET and DMPK*, **2018**, 6, 74-84	1.3	12
41	Application of Biocatalysis to on-DNA Carbohydrate Library Synthesis. *ChemBioChem*, **2017**, 18, 858-863	3.8	39

40	New reactions and reactive intermediates in the pyrolysis of cyclic phosphonium ylides. *Arkivoc*, **2017**, 2017, 293-301	0.9	
39	A new "golden age" for the antitubercular target InhA. *Drug Discovery Today*, **2017**, 22, 492-502	8.8	29
38	Präzise Lipophilie(log P)-Messungen geben Auskunft über feine stereoelektronische Effekte in der Fluorchemie. *Angewandte Chemie*, **2016**, 128, 3922-3924	3.6	3
37	Accurate Lipophilicity (log P) Measurements Inform on Subtle Stereoelectronic Effects in Fluorine Chemistry. *Angewandte Chemie - International Edition*, **2016**, 55, 3858-60	16.4	19
36	Chemoselective Sequential Click Ligations Directed by Enhanced Reactivity of an Aromatic Ynamine. *Organic Letters*, **2016**, 18, 1694-7	6.2	19
35	New direct inhibitors of InhA with antimycobacterial activity based on a tetrahydropyran scaffold. *European Journal of Medicinal Chemistry*, **2016**, 112, 252-257	6.8	16
34	Structurally Diverse Mitochondrial Branched Chain Aminotransferase (BCATm) Leads with Varying Binding Modes Identified by Fragment Screening. *Journal of Medicinal Chemistry*, **2016**, 59, 2452-67	8.3	14
33	N-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2-trans Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity. *ChemMedChem*, **2016**, 11, 687-701	3.7	21
32	The Discovery of in Vivo Active Mitochondrial Branched-Chain Aminotransferase (BCATm) Inhibitors by Hybridizing Fragment and HTS Hits. *Journal of Medicinal Chemistry*, **2015**, 58, 7140-63	8.3	22
31	Whole Cell Target Engagement Identifies Novel Inhibitors of Mycobacterium tuberculosis Decaprenylphosphoryl-β-d-ribose Oxidase. *ACS Infectious Diseases*, **2015**, 1, 615-26	5.5	36
30	Design, synthesis, and evaluation of new thiadiazole-based direct inhibitors of enoyl acyl carrier protein reductase (InhA) for the treatment of tuberculosis. *Journal of Medicinal Chemistry*, **2015**, 58, 613-24	8.3	48
29	Molecular Property Design: Does Everyone Get It?. *ACS Medicinal Chemistry Letters*, **2015**, 6, 722-5	4.3	80
28	Structure-guided optimization of small molecule c-Abl activators. *Journal of Computer-Aided Molecular Design*, **2014**, 28, 75-87	4.2	4
27	Physical Properties in Drug Design. *Topics in Medicinal Chemistry*, **2014**, 1-68	0.4	9
26	Practical purification of hydrophilic fragments and lead/drug-like molecules by reverse phase flash chromatography: tips, tricks and contemporary developments. *Drug Discovery Today*, **2013**, 18, 148-54	8.8	5
25	The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. *Drug Discovery Today*, **2011**, 16, 164-71	8.8	286
24	Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. *Drug Discovery Today*, **2011**, 16, 822-30	8.8	215
23	The successful quest for oral factor Xa inhibitors; learnings for all of medicinal chemistry?. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 6228-35	2.9	17

22	The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 1588-92	2.9	11
21	Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 1582-7	2.9	9
20	Heteroalicyclic carboxamidines as inhibitors of inducible nitric oxide synthase; the identification of (2R)-2-pyrrolidinecarboxamidine as a potent and selective haem-co-ordinating inhibitor. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 3037-40	2.9	3
19	Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity. *Drug Discovery Today*, **2010**, 15, 648-55	8.8	174
18	Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 618-22	2.9	12
17	Structure and property based design of factor Xa inhibitors: biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 28-33	2.9	21
16	Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 23-7	2.9	21
15	Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides. *Journal of Medicinal Chemistry*, **2007**, 50, 1546-57	8.3	42
14	Sulfonamide-related conformational effects and their importance in structure-based design. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 2931-4	2.9	29
13	Selective and dual action orally active inhibitors of thrombin and factor Xa. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 2927-30	2.9	20
12	New thiopyrazolo[3,4-d]pyrimidine derivatives as anti-mycobacterial agents. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 1736-40	2.9	92
11	Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 3784-8	2.9	27
10	Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 5953-7	2.9	37
9	New small-molecule synthetic antimycobacterials. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 2153-63	5.9	149
8	Preparation of heterocyclic phosphorus ylides containing the tetramic acid ring system and seven-membered ring vinylogues. *Tetrahedron Letters*, **2001**, 42, 141-143	2	14
7	Inhibition of inducible nitric oxide synthase by acetamidine derivatives of hetero-substituted lysine and homolysine. *Bioorganic and Medicinal Chemistry Letters*, **2000**, 10, 597-600	2.9	68
6	Synthesis of Amino Acid Derived Cyclic Phosphorus Ylides. *Phosphorus, Sulfur and Silicon and the Related Elements*, **1999**, 147, 245-245	1	
5	Acyl carbamate directing groups in nucleoside synthesis: Applications in the synthesis of 2?-deoxy-5-ethyl-4?-thiouridine. *Tetrahedron Letters*, **1996**, 37, 1867-1870	2	14

4	Synthesis and biological evaluation of the L-enantiomer of 2?-deoxy-5-ethyl-4?-thiouridine. *Bioorganic and Medicinal Chemistry Letters*, **1996**, 6, 991-994	2.9	23
3	Synthesis and antiviral evaluation of enantiomeric 2?,3?-dideoxy- and 2?,3?-didehydro-2?,3?-dideoxy-4?-thionucleosides. *Bioorganic and Medicinal Chemistry Letters*, **1995**, 5, 2599-2604	2.9	47
2	Anomer selectivity in 2?-deoxynucleoside synthesis: A novel approach using an acyl carbamate directing group. *Tetrahedron Letters*, **1994**, 35, 8687-8690	2	21
1	Syntheses of methylene-bridged benzopyrenes, carcinogenic components of automobile exhaust residue. *Tetrahedron Letters*, **1989**, 30, 6603-6606	2	8